Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update

Autolus Therapeutics plc (NASDAQ:AUTL) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 7,190,000 shares, a decline of 17.8% from the October 15th total of 8,750,000 shares. Based on an average daily volume of 1,120,000 shares, the days-to-cover ratio is currently 6.4 days.

Wall Street Analyst Weigh In

AUTL has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a report on Monday. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Friday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.45.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its stake in shares of Autolus Therapeutics by 253.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock worth $3,985,000 after acquiring an additional 821,156 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after purchasing an additional 2,487,778 shares during the period. Millennium Management LLC increased its holdings in Autolus Therapeutics by 113.7% in the second quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock valued at $2,829,000 after buying an additional 432,503 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock valued at $736,000 after acquiring an additional 111,131 shares during the period. Finally, Affinity Asset Advisors LLC grew its holdings in shares of Autolus Therapeutics by 27.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after acquiring an additional 925,000 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Trading Up 2.3 %

Shares of NASDAQ AUTL traded up $0.07 during mid-day trading on Friday, reaching $3.08. The company had a trading volume of 2,713,999 shares, compared to its average volume of 1,442,195. The firm has a 50 day simple moving average of $3.91 and a two-hundred day simple moving average of $3.98. Autolus Therapeutics has a 52-week low of $2.94 and a 52-week high of $7.45. The stock has a market cap of $819.56 million, a P/E ratio of -2.55 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the previous year, the business earned ($0.26) earnings per share. On average, equities analysts expect that Autolus Therapeutics will post -0.84 EPS for the current year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.